Sarepta Therapeutics Holders Approve 2026 Equity Incentive Plan and Stock Purchase Plan
At its June 4, 2026 annual meeting, Sarepta Therapeutics stockholders approved a 2026 Equity Incentive Plan and a 2026 Employee Stock Purchase Plan, both replacing earlier plans, and re-elected five Class I directors. The approvals set the share pool for employee equity compensation, a governance matter that does not change reported financial results.
Key points
- 2026 Equity Incentive Plan: up to 6,286,841 shares may be issued, replacing the 2018 plan
- 2026 Employee Stock Purchase Plan: 1,500,000 shares available for issuance, replacing the 2013 plan
- Shares entitled to vote totaled 105,571,146 as of the April 8, 2026 record date; 77.97% were present or represented
- Advisory say-on-pay vote for 2025 executive pay: 45,185,398 for and 22,373,065 against
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.